Antiplatelet, anticoagulant, and profibrinolytic activities of withaferin A

Vascular Pharmacology

Volumn 60, Issue 3, 2014, Pages 120-126

  Ku, Sae Kwang ^a   Bae, Jong Sup ^b  

^a Daegu Haany University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Anticoagulant; Fibrinolysis; HUVEC; Withaferin A

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; WITHAFERIN A; WITHANOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING TIME; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; FIBRIN POLYMERIZATION; FIBRINOLYSIS; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; PHYSIOLOGY;

ANIMALS; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED ICR; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; WITHANOLIDES;

EID: 84895527273     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.01.009     Document Type: Article

References (27)

1. Boullin D.J., Green A.R., Price K.S. The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1. J Physiol 1972, 221:415-426.
2. Dahlback B. Blood coagulation. Lancet 2000, 355:1627-1632.
3. Davie E.W. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995, 74:1-6.
4. Davie E.W., Fujikawa K., Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991, 30:10363-10370.
5. Dejana E., Callioni A., Quintana A., de Gaetano G. Bleeding time in laboratory animals. II - a comparison of different assay conditions in rats. Thromb Res 1979, 15:191-197.
6. Essawi T., Srour M. Screening of some Palestinian medicinal plants for antibacterial activity. J Ethnopharmacol 2000, 70:343-349.
7. Fares A. Winter cardiovascular diseases phenomenon. N Am J Med Sci 2013, 5:266-279.
8. Ghosh S., Ezban M., Persson E., Pendurthi U., Hedner U., Rao L.V. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 2007, 5:336-346.
9. Goto S., Tamura N., Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 2004, 44:316-323.
10. Hamaguchi E., Takamura T., Shimizu A., Nagai Y. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther 2003, 307:987-994.
11. Izuhara Y., Takahashi S., Nangaku M., Takizawa S., Ishida H., Kurokawa K., et al. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 2008, 28:672-677.
12. Kaileh M., Vanden Berghe W., Heyerick A., Horion J., Piette J., Libert C., et al. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem 2007, 282:4253-4264.
13. Kim D.C., Ku S.K., Bae J.S. Anticoagulant activities of curcumin and its derivative. BMB Rep 2012, 45:221-226.
14. Kim S.Y., Kim S., Kim J.M., Jho E.H., Park S., Oh D., et al. PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. BMB Rep 2011, 44:140-145.
15. Kim T.H., Ku S.K., Bae J.S. Antithrombotic and profibrinolytic activities of eckol and dieckol. J Cell Biochem 2012, 113:2877-2883.
16. Lee K.H. Research and future trends in the pharmaceutical development of medicinal herbs from Chinese medicine. Public Health Nutr 2000, 3:515-522.
17. Lee W., Yang E.J., Ku S.K., Song K.S., Bae J.S. Anticoagulant activities of oleanolic acid via inhibition of tissue factor expressions. BMB Rep 2012, 45:390-395.
18. Li Y., Qian Z.J., Ryu B., Lee S.H., Kim M.M., Kim S.K. Chemical components and its antioxidant properties in vitro: an edible marine brown alga, Ecklonia cava. Bioorg Med Chem 2009, 17:1963-1973.
19. Lopez S., Peiretti F., Bonardo B., Juhan-Vague I., Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 2000, 152:359-366.
20. Mann K.G., Brummel K., Butenas S. What is all that thrombin for?. J Thromb Haemost 2003, 1:1504-1514.
21. Nowak P., Zbikowska H.M., Ponczek M., Kolodziejczyk J., Wachowicz B. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thromb Res 2007, 121:163-174.
22. Philip-Joet F., Alessi M.C., Philip-Joet C., Aillaud M., Barriere J.R., Arnaud A., et al. Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 1995, 8:1352-1356.
23. Quinn C., Hill J., Hassouna H. A guide for diagnosis of patients with arterial and venous thrombosis. Clin Lab Sci 2000, 13:229-238.
24. Qureshi S.H., Manithody C., Bae J.S., Yang L., Rezaie A.R. Autolysis loop restricts the specificity of activated protein C: analysis by FRET and functional assays. Biophys Chem 2008, 134:239-245.
25. Rao L.V., Rapaport S.I., Lorenzi M. Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 1988, 71:791-796.
26. Schleef R.R., Bevilacqua M.P., Sawdey M., Gimbrone M.A., Loskutoff D.J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988, 263:5797-5803.
27. Sugo T., Nakamikawa C., Tanabe S., Matsuda M. Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. J Biochem 1995, 117:244-250.